Sam Kintz compensation by year
Enliven Therapeutics Summary Compensation Table · all 4 fiscal years held| Component | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Salary | $400,000 | $561,190 | $600,000 | $624,154 |
| Bonus | $0 | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $0 | $0 |
| Option awards | $126,839 | $7,413,342 | $4,487,860 | $7,952,553 |
| Non-equity incentive | $195,000 | $302,500 | $360,000 | $316,800 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 |
| All other | $2,000 | $2,719 | $13,800 | $15,140 |
| Total | $723,839 | $8,279,751 | $5,461,660 | $8,908,647 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Enliven Therapeutics, Inc. DEF 14A filed April 27, 2026, accession 0001193125-26-182045, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Enliven Therapeutics, Inc. filed document, accession 0001193125-26-182045. Every figure is read from that document and cited to the page and table it appears in. Filed April 27, 2026.
Enliven Therapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Richard Fair | President and Chief Executive Officer | $11,918,926 |
| Sam Kintz · this page | Former President and Chief Executive Officer | $8,908,647 |
| Helen Collins | Chief Medical Officer | $3,501,699 |
| Ben Hohl | Chief Financial Officer | $3,443,173 |
Board service
Enliven Therapeutics board · FY2023How this board is paid
Company policy: Enliven Therapeutics pays directors a $35,000 cash retainer and $250,000 in Options. As stated in Enliven Therapeutics's FY2023 proxy.
The full Enliven Therapeutics compensation record
free company briefThis page is one person within Enliven Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Enliven Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.